Skip to main content

Table 3 Medication use

From: Cognitive-behavioural therapy has no effect on disease activity but improves quality of life in subgroups of patients with inflammatory bowel disease: a pilot randomised controlled trial

 

+CBT

SC

 

n (%)

 

Baseline

6 months

12 months

Baseline

6 months

12 months

n = 90

n = 51

n = 42

n = 84

n = 65

n = 64

Azathioprine

44 (49)

21 (41)

16 (38)

22 (26)

16 (25)

16 (25)

Mesalazine

25 (28)

11 (22)

10 (24)

32 (38)

20 (31)

22 (34)

Sulphasalazine

13 (14)

6 (12)

7 (16)

14 (17)

12 (18)

10 (15)

Corticosteroids

10 (11)

6 (12)

3 (7)

8 (9)

5 (8)

6 (9)

Adalimumab

10 (11)

7 (14)

2 (5)

6 (7)

4 (6)

4 (6)

Infliximab

10 (11)

8 (16)

5 (12)

5 (6)

5 (8)

6 (9)

Vedolizumab

3 (3)

1 (2)

1 (2)

1 (1)

0

0

Methotrexate

4 (4)

4 (8)

2 (5)

4 (5)

2 (3)

2 (3)

Mercaptopurine/thiopurine

2 (2)

2 (4)

5 (12)

4 (5)

0

5 (8)

Vitamins

28 (31)

12 (23)

6 (14)

23 (27)

12 (18)

11 (17)

Fish oil

17 (19)

12 (23)

9 (21)

11 (13)

9 (14)

6 (9)

Probiotics

11 (12)

5 (10)

5 (12)

7 (8)

6 (9)

6 (9)

Paracetamol

24 (27)

14 (27)

10 (24)

18 (21)

10 (15)

11 (17)

Codeine

10 (11)

3 (6)

4 (9)

4 (5)

4 (6)

3 (5)

Ibuprofen

6 (7)

2 (4)

2 (5)

3 (4)

1 (1)

1 (1)

Dextropropoxyphene

4 (4)

1 (2)

0

1 (1)

1 (1)

0

Antispasmodics

2 (2)

1 (2)

1 (2)

1 (1)

2 (3)

4 (6)

Morphine

1 (1)

0

0

2 (2)

0

1 (1)

Oxycodone hydrochloride

1 (1)

3 (6)

2 (2)

2 (2)

3 (5)

0

Tramadol

1 (1)

0

0

1 (1)

0

0

Naproxen

0

1 (2)

0

0

0

0

Medication for depression

24 (28)

14 (29)

10 (24)

20 (27)

12 (18)

12 (19)